atenolol has been researched along with Coronary Disease in 206 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine." | 9.17 | [Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "The aim of the study was to estimate clinical and functional indices under stable course of coronary heart disease (CHD) against the background of therapy with coraxan and atenolol." | 9.13 | [Coraxan and atenolol: similarities and differences in correction of clinical and functional indices in therapy of patients with coronary heart disease]. ( Biriuchenko, MV; Kapelovich, VIu; Pozdniakova, NV; Tatarchenko, IP, 2008) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 9.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively." | 9.06 | Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. ( Keller, N; Larsen, J; Storm, T; Sykulski, R; Thamsborg, G, 1988) |
| "The effects of theophylline (400 mg twice a day), atenolol (50 mg twice a day) and their combination on myocardial ischemia were studied in 9 patients with stable angina pectoris in a randomized, single-blind, triple crossover trial." | 9.06 | Effects of theophylline, atenolol and their combination on myocardial ischemia in stable angina pectoris. ( Crea, F; Davies, GJ; el-Tamimi, H; Galassi, AR; Kaski, JC; Maseri, A; Pupita, G, 1990) |
| "Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients." | 9.06 | Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988) |
| "In a randomized, placebo-controlled double-blind cross-over study the effect and duration of effect of 2% nitroglycerin ointment (2 cm/m2 body surface) and 50 mg atenolol, as the only drug or the two in combination, were tested on 16 patients with coronary heart disease." | 9.05 | [Effect of atenolol and nitroglycerin ointment on exertion tolerance in coronary disease]. ( Diehm, C; Koenig, W, 1983) |
| "Pain relief in acute myocardial infarction (AMI) by the beta-adrenoceptor antagonist, atenolol, was demonstrated by three separate studies." | 9.05 | Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. ( Bennett, DH; Bray, CL; Cruickshank, JM; Faragher, EB; Ramsdale, DR; Sleight, P; Ward, C; Yusuf, S, 1982) |
| "A randomised, double-blind, placebo controlled study of morbidity and mortality was carried out using heparin, atenolol, and a combination of both drugs, in 214 patients with the intermediate coronary syndrome." | 9.05 | Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. ( Telford, AM; Wilson, C, 1981) |
| "The effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, on ischemic myocardial acidosis were studied in dog hearts, in which the left anterior descending coronary artery was partially occluded for 90 min, and were compared with those of atenolol and propranolol." | 7.68 | Betaxolol, a cardioselective beta-adrenoceptor antagonist, attenuates ischemic myocardial acidosis in dogs. ( Abe, Y; Narimatsu, A; Tobe, A, 1990) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 6.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Atenolol is a pure beta 1-selective antagonist with more pronounced effects on blood pressure and heart rate at rest." | 6.67 | The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. ( Boberg, J; Larsen, FF; Pehrsson, SK, 1992) |
| "Cicloprolol is a new cardioselective beta-blocking agent with partial agonist activity (intrinsic sympathomimetic activity, ISA)." | 6.66 | Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease. ( Frais, MA; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1989) |
| " In a double-blind study of ten patients with stable angina pectoris treated with nifedipine, propranolol, and atenolol, smoking was found to have direct and adverse effects on the heart and to interfere with the efficacy of all three antianginal drugs, but with that of nifedipine the most." | 6.16 | Smoking, catecholamines, and the ischemic myocardium. ( Fox, KM, 1988) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 5.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| "To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine." | 5.17 | [Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome]. ( Bespalova, LD; Kalyuzhin, VV; Kalyuzhina, EV; Kolesnikov, RN; Pushnikova, EY; Teplyakov, AT, 2013) |
| "We have reported the benefits of atorvastatin and of an amlodipine-based regimen on coronary heart disease (CHD) events in hypertensive patients in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)." | 5.14 | Coronary heart disease benefits from blood pressure and lipid-lowering. ( Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "The aim of this study was to evaluate the effect of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in patients with hypertension uncomplicated by coronary heart disease in the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm)." | 5.14 | Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). ( Campbell, NR; Dahlöf, B; Dobson, JE; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "The aim of the study was to estimate clinical and functional indices under stable course of coronary heart disease (CHD) against the background of therapy with coraxan and atenolol." | 5.13 | [Coraxan and atenolol: similarities and differences in correction of clinical and functional indices in therapy of patients with coronary heart disease]. ( Biriuchenko, MV; Kapelovich, VIu; Pozdniakova, NV; Tatarchenko, IP, 2008) |
| "The Circadian Anti-ischemia Program in Europe (CAPE II) compared the efficacy of amlodipine and diltiazem (Adizem XL) and the combination of amlodipine/atenolol and diltiazem (Adizem XL)/isosorbide 5-mononitrate on exercise and ambulatory myocardial ischemia during regular therapy and after omission of medication." | 5.10 | Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. ( Beckerman, B; Brennan, C; Bultas, J; Deanfield, JE; Detry, JM; Lichtlen, PR; Sellier, P; Thaulow, E; Young, ST, 2002) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 5.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "This randomized, double-blind, parallel study compared the anti-anginal effects of nicorandil and atenolol in 37 patients with exercise-induced angina pectoris." | 5.07 | A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. ( Hughes, LO; Lahiri, A; Raftery, EB; Rose, EL, 1993) |
| "In a large randomised trial of early beta-blockade in acute myocardial infarction (ISIS-1), almost all the reduction in mortality associated with the use of atenolol occurred on the day of admission or on the subsequent day." | 5.06 | Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. ( , 1988) |
| "We have used a modified noninvasive echo-Doppler cardiac output device, based on the principle of attenuated compensation volume flow, to assess the cardiovascular effects of the slow-calcium antagonist nicardipine in coronary disease." | 5.06 | Hemodynamic assessment of nicardipine alone and with atenolol in coronary artery disease using a modified echo-Doppler device. ( Silke, B; Taylor, SH; Verma, SP; Zezulka, AV, 1989) |
| "The efficacy and toleration of doxazosin and atenolol were compared over a 52-week period in a double-blind, multicenter study of 228 patients with mild-to-moderate hypertension." | 5.06 | Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. ( Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988) |
| "The effects of theophylline (400 mg twice a day), atenolol (50 mg twice a day) and their combination on myocardial ischemia were studied in 9 patients with stable angina pectoris in a randomized, single-blind, triple crossover trial." | 5.06 | Effects of theophylline, atenolol and their combination on myocardial ischemia in stable angina pectoris. ( Crea, F; Davies, GJ; el-Tamimi, H; Galassi, AR; Kaski, JC; Maseri, A; Pupita, G, 1990) |
| "Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients." | 5.06 | Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988) |
| "Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively." | 5.06 | Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. ( Keller, N; Larsen, J; Storm, T; Sykulski, R; Thamsborg, G, 1988) |
| " We have utilised a new non-imaging echo-Doppler cardiac output device, using the principle of attenuated compensated volume flow (ACVF), to assess the cardiovascular effects of atenolol and buccal nitroglycerin (NTG) in a placebo-controlled study of 30 patients with coronary disease." | 5.06 | Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device. ( Silke, B; Taylor, SH; Verma, SP, 1990) |
| "In a randomized, placebo-controlled double-blind cross-over study the effect and duration of effect of 2% nitroglycerin ointment (2 cm/m2 body surface) and 50 mg atenolol, as the only drug or the two in combination, were tested on 16 patients with coronary heart disease." | 5.05 | [Effect of atenolol and nitroglycerin ointment on exertion tolerance in coronary disease]. ( Diehm, C; Koenig, W, 1983) |
| "Pain relief in acute myocardial infarction (AMI) by the beta-adrenoceptor antagonist, atenolol, was demonstrated by three separate studies." | 5.05 | Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. ( Bennett, DH; Bray, CL; Cruickshank, JM; Faragher, EB; Ramsdale, DR; Sleight, P; Ward, C; Yusuf, S, 1982) |
| "A randomised, double-blind, placebo controlled study of morbidity and mortality was carried out using heparin, atenolol, and a combination of both drugs, in 214 patients with the intermediate coronary syndrome." | 5.05 | Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. ( Telford, AM; Wilson, C, 1981) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "The aim of this study was to investigate the effect of a beta-blocker (atenolol and metoprolol) on exercise heart rate (HR) and rate pressure product (RPP) during a morning and afternoon maximal exercise test (maxET) in patients with coronary heart disease (CHD)." | 3.74 | Time-of-day variation in cardiovascular response to maximal exercise testing in coronary heart disease patients taking a beta-blocker. ( Boulay, P; Dufour Doiron, M; Prud'homme, D, 2007) |
| "Atenolol was tested for its effect on the fatty acid spectrum of serum low-density lipoproteins in patients with coronary heart disease in winter and summer." | 3.74 | [Management of coronary heart disease: seasonal features]. ( Briuzgina, TS; Pilipchak, EM, 2007) |
| " A verapamil SR strategy is an alternative to an atenolol strategy for the treatment of Hispanic patients with hypertension and CAD and can reduce the risk of new-onset diabetes." | 3.73 | Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). ( Aranda, JM; Cangiano, JL; Conti, CR; Cooper-DeHoff, RM; Garcia-Barreto, D; Gaxiola, E; Hewkin, A; Pepine, CJ, 2006) |
| "To understand the effects of single- and multiple-drug combinations for hypertension on the risk of adverse clinical outcomes, the authors analyzed data from the International Verapamil SR/Trandolapril Study (INVEST)." | 3.73 | A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. ( Cooper-DeHoff, R; Elliott, WJ; Hewkin, AC; Kupfer, S; Pepine, CJ, 2005) |
| "In the present study, 20 patients with both hypertension and stabile angina pectoris were treated twice daily for 6 months with 50 mg atenolol and 20 mg retard-formulation nifedipine." | 3.68 | [Therapy of hypertensive coronary patients. Open long-term study with a combination of atenolol and nifedipine]. ( Lindner, UK, 1991) |
| "The effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, on ischemic myocardial acidosis were studied in dog hearts, in which the left anterior descending coronary artery was partially occluded for 90 min, and were compared with those of atenolol and propranolol." | 3.68 | Betaxolol, a cardioselective beta-adrenoceptor antagonist, attenuates ischemic myocardial acidosis in dogs. ( Abe, Y; Narimatsu, A; Tobe, A, 1990) |
| "To investigate whether the lower the blood pressure (BP) the better the prognosis for the patient with moderate-to-severe hypertension, an assessment was made of 902 patients who received the beta 1-selective beta-blocker atenolol (median dose 100 mg a day), either alone or with other antihypertensive agents, for up to 10 years (mean 6." | 3.67 | Benefits and potential harm of lowering high blood pressure. ( Cruickshank, JM; Thorp, JM; Zacharias, FJ, 1987) |
| " The mean difference between aortic systolic pressures measured from direct radial waveforms and from derived aortic pressure between 3 and 5 h after dosing under all circumstances was 1." | 2.73 | Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure. ( Adji, A; Hirata, K; Hoegler, S; O'Rourke, MF, 2007) |
| "Carvedilol is a direct inhibitor of vascular smooth muscle cell migration and proliferation through inhibition of mitogen-activated protein kinase activity and regulation of cell cycle progression." | 2.71 | Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. ( Cha, KS; Kim, DI; Kim, DS; Kim, HJ; Kim, JS; Kim, JW; Kim, MH, 2004) |
| "Tedisamil is a new bradycardic agent proven to exert antiischemic and antiarrhythmic effects by blockade of the cellular cardiac repolarization K+ currents as well as of multiple neuronal and vascular K+ currents (Ito, Ik, and K+ATP)." | 2.69 | Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists. ( Hamm, C; Mitrovic, V; Oehm, E; Pitschner, H; Thormann, J, 2000) |
| "The reduction in coronary disease is consistent with predictions based on prospective epidemiological studies and is concordant with other recent intervention trials." | 2.67 | Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. ( , 1993) |
| "Atenolol is a pure beta 1-selective antagonist with more pronounced effects on blood pressure and heart rate at rest." | 2.67 | The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. ( Boberg, J; Larsen, FF; Pehrsson, SK, 1992) |
| "Treatment with diltiazem resulted in a significant lengthening of sinus cycle length (SCL, p < 0." | 2.67 | Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy. ( Biscione, F; Lanza, GA; Manzoli, A; Natale, A; Santarelli, P, 1994) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 2.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| " The chronic use of beta adrenergic blockers (BAB) has been associated with reductions in HDL-cholesterol (HDL-C) and increases in triglycerides (TG)." | 2.66 | Alterations in plasma lipids consequent to endurance training and beta-blockade. ( Ewy, GA; Freund, BJ; Hartzell, AA; Jilka, SM; Joyner, MJ; Morton, AR; Stanforth, PR; Wilmore, JH, 1989) |
| "Nifedipine was not better than placebo." | 2.66 | Atenolol and/or nifedipine in effort angina: which is the treatment of choice for exercise coronary protection? ( Caiazzo, MR; Carella, G; Chiariello, M; Condorelli, M; Cotecchia, MR; de Arcangelis, E; Di Maro, T; Romano, M, 1988) |
| "Cicloprolol is a new cardioselective beta-blocking agent with partial agonist activity (intrinsic sympathomimetic activity, ISA)." | 2.66 | Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease. ( Frais, MA; Reynolds, G; Sharma, SK; Silke, B; Taylor, SH; Verma, SP, 1989) |
| "Celiprolol is a novel cardioselective beta-blocking agent with attributed cardio-stimulating properties." | 2.66 | Differential actions of atenolol and celiprolol on cardiac performance in ischemic heart disease. ( Frais, MA; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1986) |
| " Chronic oral administration of nifedipine in combination with atenolol precipitated LV failure only in those with the lowest EF and highest LVEDP; usually LV failure was present with atenolol alone." | 2.66 | Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function. ( de Buitleir, M; Krikler, DM; Rowland, E, 1985) |
| "Atenolol is an alternative drug in the treatment of PVC in patients with coronary heart disease." | 2.65 | [Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)]. ( Brandes, JW; Körst, HA; Lembcke, HJ; Littmann, KP, 1981) |
| "Atenolol was the beta-blocker most used." | 2.55 | Beta-blockers for hypertension. ( Bradley, HA; Mayosi, BM; Opie, LH; Volmink, J; Wiysonge, CS, 2017) |
| "Initiating treatment of hypertension with beta-blockers leads to modest reductions in cardiovascular disease and no significant effects on mortality." | 2.48 | Beta-blockers for hypertension. ( Bradley, HA; Mayosi, BM; Mbewu, A; Opie, LH; Volmink, J; Wiysonge, CS, 2012) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "Allergic reactions, including anaphylactoid shock due to contrast material, are not uncommon." | 2.39 | Refractory anaphylactoid shock potentiated by beta-blockers. ( Javeed, H; Javeed, N; Javeed, S; Moussa, G; Rezai, F; Wong, P, 1996) |
| "Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours." | 2.38 | Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. ( Brogden, RN; Murdoch, D; Wadworth, AN, 1991) |
| "Heart failure is characterized by the inability of the myocardium to shorten sufficiently or to eject an adequate stroke volume to maintain normal perfusion of both the cardiac and the extracardiac organs." | 2.38 | Beta-blocking agents in heart failure: modern concepts and overview. ( Strauer, BE, 1990) |
| " A prolongation of propranolol biological half-life from 5." | 1.35 | Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ( Auler, JO; Carmona, MJ; Malbouisson, LM; Pereira, VA; Santos, SR, 2009) |
| "Indications for treatment were hypertension (75%), coronary artery disease with (12%) or without (3%) hypertension, or unknown (10%)." | 1.30 | Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. ( Danser, AH; Hense, HW; Holmer, SR; Mayer, B; Riegger, GA; Schunkert, H, 1998) |
| " The author assumes that in addition to the effectiveness of the administered drug the marked improvement of the patients is due to better collaboration of the patients and adherence to the prescribed dosage and lifestyle." | 1.29 | [Corotenol, its effectiveness and tolerance in light of new studies]. ( Uhlír, O, 1996) |
| "Naloxone alone reduced arrhythmia incidence but to a lesser extent than U-50,488H." | 1.28 | Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion. ( Penz, WP; Pugsley, MK; Walker, MJ; Wong, TM, 1992) |
| "8." | 1.28 | Mechanisms underlying the antiarrhythmic properties of beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats. ( Abraham, S; Beatch, GN; Paletta, MJ; Walker, MJ, 1989) |
| " Thus at the dosage used felodipine was a potent dilator of systemic arterioles but had no direct effect on left ventricular function." | 1.27 | Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease. ( Culling, W; Ruttley, MS; Sheridan, DJ, 1984) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 1.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| " In NL-AMI, pretreatment of cats with D at the same dosage (intravenous infusion) reduced AMI-ST segment increases and AMI changes in hemodynamics." | 1.27 | Cardioprotective effects of defibrotide in acute lethal and nonlethal myocardial ischemia in the cat. ( Berti, F; Mantovani, M; Niada, R; Pescador, R; Porta, R; Prino, G, 1986) |
| "With acute progressive stenosis, a nearly linear relation was found between normalized subendocardial flow and function." | 1.27 | Regional myocardial blood flow and function in experimental myocardial ischemia. ( Gallagher, KP; Goldfarb, R; Guth, B; Lee, JD; Matzusaki, M; Ross, J, 1986) |
| "Metoprolol was found to be significantly more efficiently distributed to the ischemic myocardium than atenolol in all three species." | 1.27 | Cardiac anti-ischemic effect of metoprolol: role of beta-blockade within the ischemic region. ( Ablad, B; Abrahamsson, T; Adler, G; Björkman, JA; Bjurö, T; Ek, L; Ervik, M; Sjöquist, PO; Sutherland, I; Svensson, L, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 96 (46.60) | 18.7374 |
| 1990's | 74 (35.92) | 18.2507 |
| 2000's | 28 (13.59) | 29.6817 |
| 2010's | 8 (3.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Sun, N | 1 |
| Jiang, X | 1 |
| Xi, Y | 1 |
| Kalyuzhin, VV | 1 |
| Teplyakov, AT | 1 |
| Pushnikova, EY | 1 |
| Bespalova, LD | 1 |
| Kalyuzhina, EV | 1 |
| Kolesnikov, RN | 1 |
| Wiysonge, CS | 2 |
| Bradley, HA | 2 |
| Volmink, J | 2 |
| Mayosi, BM | 2 |
| Opie, LH | 4 |
| Füessl, HS | 2 |
| Pacanowski, MA | 1 |
| Gong, Y | 1 |
| Cooper-Dehoff, RM | 2 |
| Schork, NJ | 1 |
| Shriver, MD | 1 |
| Langaee, TY | 1 |
| Pepine, CJ | 7 |
| Johnson, JA | 1 |
| Sever, PS | 4 |
| Poulter, NR | 4 |
| Mastorantonakis, S | 1 |
| Chang, CL | 1 |
| Dahlof, B | 4 |
| Wedel, H | 4 |
| Bangalore, S | 1 |
| Messerli, FH | 1 |
| Franklin, SS | 1 |
| Mancia, G | 1 |
| Champion, A | 1 |
| Carmona, MJ | 1 |
| Pereira, VA | 1 |
| Malbouisson, LM | 1 |
| Auler, JO | 1 |
| Santos, SR | 1 |
| Dobson, JE | 1 |
| Campbell, NR | 1 |
| Reyes, E | 1 |
| Stirrup, J | 1 |
| Roughton, M | 1 |
| D'Souza, S | 1 |
| Underwood, SR | 1 |
| Anagnostopoulos, C | 1 |
| Mbewu, A | 1 |
| Deanfield, JE | 1 |
| Detry, JM | 1 |
| Sellier, P | 1 |
| Lichtlen, PR | 2 |
| Thaulow, E | 1 |
| Bultas, J | 1 |
| Brennan, C | 1 |
| Young, ST | 1 |
| Beckerman, B | 1 |
| Schmieder, RE | 1 |
| Schneider, MP | 1 |
| Bossi, M | 1 |
| Tiberti, G | 1 |
| Cruickshank, JM | 4 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Talbert, RL | 1 |
| Pieper, JA | 1 |
| Ito, MK | 1 |
| Cha, KS | 1 |
| Kim, MH | 1 |
| Kim, JW | 1 |
| Kim, DI | 1 |
| Kim, HJ | 1 |
| Kim, DS | 1 |
| Kim, JS | 1 |
| Elliott, WJ | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Cooper-DeHoff, R | 1 |
| Baumgart, P | 1 |
| Aranda, JM | 1 |
| Gaxiola, E | 1 |
| Cangiano, JL | 1 |
| Garcia-Barreto, D | 1 |
| Conti, CR | 2 |
| Hewkin, A | 1 |
| Dufour Doiron, M | 1 |
| Prud'homme, D | 1 |
| Boulay, P | 1 |
| Pilipchak, EM | 1 |
| Briuzgina, TS | 1 |
| Rahn, KH | 1 |
| Adji, A | 1 |
| Hirata, K | 1 |
| Hoegler, S | 1 |
| O'Rourke, MF | 1 |
| Tatarchenko, IP | 1 |
| Pozdniakova, NV | 1 |
| Kapelovich, VIu | 1 |
| Biriuchenko, MV | 1 |
| Johansson, SR | 1 |
| McCall, M | 1 |
| Wilhelmsson, C | 1 |
| Vedin, JA | 1 |
| Bush, LR | 1 |
| Haack, DW | 1 |
| Shlafer, M | 1 |
| Lucchesi, BR | 1 |
| Telford, AM | 1 |
| Wilson, C | 1 |
| Ramsdale, DR | 1 |
| Faragher, EB | 1 |
| Bennett, DH | 1 |
| Bray, CL | 1 |
| Ward, C | 1 |
| Yusuf, S | 1 |
| Sleight, P | 1 |
| Hjalmarson, A | 1 |
| Henderson, A | 1 |
| Sheridan, D | 1 |
| Ross, J | 9 |
| Lewis, M | 1 |
| Thandroyen, FT | 1 |
| Worthington, MG | 1 |
| Higginson, LM | 1 |
| Johns, VJ | 1 |
| Matsuzaki, M | 5 |
| Patritti, J | 1 |
| Tajimi, T | 3 |
| Miller, M | 1 |
| Kemper, WS | 2 |
| Körst, HA | 2 |
| Brandes, JW | 2 |
| Lembcke, HJ | 1 |
| Littmann, KP | 2 |
| Pedersen, SU | 1 |
| Giudicelli, JF | 5 |
| Berdeaux, A | 5 |
| Tato, F | 2 |
| Garnier, M | 2 |
| Lubbe, WF | 1 |
| Muller, CA | 1 |
| Worthington, M | 1 |
| McFadyen, EL | 1 |
| Bass, C | 1 |
| Koenig, W | 1 |
| Diehm, C | 1 |
| Culling, W | 1 |
| Ruttley, MS | 1 |
| Sheridan, DJ | 1 |
| Fagard, R | 1 |
| Reybrouck, T | 1 |
| Vanhees, L | 1 |
| Cattaert, A | 1 |
| Vanmeenen, T | 1 |
| Grauwels, R | 1 |
| Amery, A | 1 |
| Wang, ZH | 1 |
| Schmieder, R | 2 |
| Friedrich, G | 2 |
| Neus, H | 2 |
| Rüdel, H | 1 |
| von Eiff, AW | 2 |
| Khadzhipetrov, N | 1 |
| Georgiev, S | 1 |
| Kogan, AKh | 1 |
| Kudrin, AN | 1 |
| Mashkovskiĭ, MD | 1 |
| Miez-Gombyn, A | 1 |
| Iuzhakov, SD | 1 |
| Adamska-Dyniewska, H | 1 |
| Pruszczyński, J | 1 |
| Trela, R | 1 |
| Bischoff, K | 1 |
| Mellini, M | 1 |
| Robutti, A | 1 |
| Mattiauda, C | 1 |
| Cavazzana, G | 1 |
| Roych, C | 1 |
| Sanfelici, D | 1 |
| Baccino, M | 1 |
| Reforzo, F | 1 |
| Simonsen, S | 1 |
| Frishman, WH | 1 |
| Rüddel, H | 1 |
| Vilaine, JP | 1 |
| Chlup, J | 1 |
| Engel, HJ | 2 |
| Pretschner, P | 1 |
| Sanchez-Cascos, A | 1 |
| Motté, G | 1 |
| Chanu, B | 1 |
| Sébag, C | 1 |
| Bénaim, P | 1 |
| Merrick, AF | 1 |
| Odom, NJ | 1 |
| Keenan, DJ | 1 |
| Grotte, GJ | 1 |
| Airaksinen, KE | 2 |
| Niemelä, MJ | 2 |
| Huikuri, HV | 2 |
| Santarelli, P | 1 |
| Biscione, F | 1 |
| Natale, A | 1 |
| Manzoli, A | 1 |
| Lanza, GA | 1 |
| Ruf, G | 1 |
| Trenk, D | 1 |
| Jähnchen, E | 1 |
| Roskamm, H | 1 |
| Knatterud, GL | 1 |
| Bourassa, MG | 1 |
| Geller, NL | 1 |
| Sopko, G | 1 |
| Chaitman, BR | 1 |
| Pratt, C | 1 |
| Stone, PH | 1 |
| Davies, RF | 1 |
| Rogers, WJ | 1 |
| Foale, RA | 1 |
| Raftery, EB | 1 |
| Lahiri, A | 1 |
| Hughes, LO | 1 |
| Rose, EL | 1 |
| Carruthers, G | 1 |
| Dessain, P | 1 |
| Fodor, G | 1 |
| Newman, C | 1 |
| Palmer, W | 1 |
| Sim, D | 1 |
| Franklin, BA | 1 |
| Gordon, S | 1 |
| Timmis, GC | 1 |
| Schweizer, J | 1 |
| Kaulen, R | 1 |
| Altmann, E | 1 |
| Nierade, A | 1 |
| Nanning, T | 1 |
| Mulcahy, D | 3 |
| Dargie, HJ | 2 |
| Ford, I | 1 |
| Fox, KM | 4 |
| Uhlír, O | 1 |
| van Campen, CM | 1 |
| Visser, FC | 1 |
| Visser, CA | 1 |
| Javeed, N | 1 |
| Javeed, H | 1 |
| Javeed, S | 1 |
| Moussa, G | 1 |
| Wong, P | 1 |
| Rezai, F | 1 |
| Bashour, TT | 1 |
| Espinosa, E | 1 |
| Blumenthal, J | 1 |
| Wong, T | 1 |
| Mason, DT | 1 |
| Killip, T | 1 |
| Ho, T | 1 |
| Taussig, D | 1 |
| McAnulty, G | 1 |
| Devereaux, PJ | 1 |
| Ghali, WA | 1 |
| Chazan, R | 1 |
| Daae, LN | 1 |
| Westlie, L | 3 |
| Pierdomenico, SD | 1 |
| Bucci, A | 1 |
| Costantini, F | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Mezzetti, A | 1 |
| Weissman, NJ | 1 |
| Sheris, SJ | 1 |
| Picard, MH | 1 |
| Bach, DS | 1 |
| Sklar, J | 1 |
| Cohen, JL | 1 |
| Holmer, SR | 1 |
| Hense, HW | 1 |
| Danser, AH | 1 |
| Mayer, B | 1 |
| Riegger, GA | 1 |
| Schunkert, H | 1 |
| Nozawa, T | 1 |
| Inoue, H | 1 |
| Newton, GE | 1 |
| Azevedo, ER | 1 |
| Parker, JD | 1 |
| Fragasso, G | 2 |
| Xuereb, RG | 1 |
| Xuereb, M | 1 |
| Rossetti, E | 2 |
| Margonato, A | 1 |
| Chierchia, SL | 2 |
| Julius, BK | 1 |
| Vassalli, G | 1 |
| Mandinov, L | 1 |
| Hess, OM | 1 |
| Rentoukas, EI | 1 |
| Deftereos, SG | 1 |
| Alpert, MA | 1 |
| Nikas, DJ | 1 |
| Lazaros, GA | 1 |
| Petropoulou, EN | 1 |
| Zacharoulis, AA | 1 |
| Forbes, CD | 1 |
| Lowe, GD | 1 |
| MacLaren, M | 1 |
| Shaw, BG | 1 |
| Dickinson, JP | 1 |
| Kieffer, G | 1 |
| Mellone, R | 1 |
| Vanzulli, A | 1 |
| Del Maschio, A | 1 |
| Owens, P | 1 |
| O'Brien, E | 2 |
| Mitrovic, V | 1 |
| Oehm, E | 1 |
| Thormann, J | 1 |
| Pitschner, H | 1 |
| Hamm, C | 1 |
| Burger, W | 1 |
| Hampel, C | 1 |
| Kaltenbach, M | 1 |
| Hartmann, A | 1 |
| Herrmann, M | 1 |
| Hoffmann, JA | 1 |
| Klepzig, H | 1 |
| Bory, M | 1 |
| Mulcahy, DA | 1 |
| Strauer, BE | 2 |
| Beevers, G | 1 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Kjeldsen, SE | 1 |
| McInnes, GT | 1 |
| Mehlsen, J | 1 |
| Nieminen, M | 1 |
| Ostergren, J | 1 |
| Jenkins, NP | 1 |
| Keevil, BG | 1 |
| Hutchinson, IV | 1 |
| Brooks, NH | 1 |
| Boissier, JR | 2 |
| Hugues, FC | 1 |
| Julien, D | 1 |
| Marche, J | 1 |
| Amende, I | 2 |
| Simon, R | 2 |
| Hood, WP | 1 |
| Lightlen, PR | 1 |
| Robinson, C | 2 |
| Birkhead, J | 1 |
| Crook, B | 1 |
| Jennings, K | 1 |
| Jewitt, D | 2 |
| Jackson, G | 1 |
| Fisk, C | 1 |
| Degenring, FH | 1 |
| Degenering, FW | 1 |
| Wiegand, V | 1 |
| Güggi, M | 1 |
| Meesmann, W | 2 |
| Kessler, M | 1 |
| Greitschus, F | 1 |
| Langbehn, AF | 1 |
| Burmeister, G | 1 |
| Horst, H | 1 |
| Sonntag, F | 1 |
| Klempien, EJ | 1 |
| Stephens, J | 1 |
| Hayward, R | 1 |
| Ead, H | 1 |
| Adams, L | 1 |
| Hamer, J | 1 |
| Spurrell, R | 1 |
| Abendroth, RR | 1 |
| Stephan, K | 1 |
| Schley, G | 1 |
| Hübner, H | 1 |
| Lichtlen, P | 2 |
| Hundeshagen, H | 1 |
| Dileep-Kumar, P | 1 |
| Sahasranam, KV | 1 |
| Nair, RG | 1 |
| Boberg, J | 1 |
| Larsen, FF | 1 |
| Pehrsson, SK | 1 |
| Stoschitzky, K | 1 |
| Lindner, W | 1 |
| Klein, W | 1 |
| Ménard, J | 1 |
| Chatellier, G | 1 |
| el-Tamimi, H | 2 |
| Davies, GJ | 2 |
| Ferraro, S | 1 |
| Maddalena, G | 1 |
| D'Agosto, V | 1 |
| D'Alto, M | 1 |
| Fazio, S | 1 |
| Santomauro, M | 1 |
| Romano, M | 2 |
| Chiariello, M | 2 |
| Ulianova, KN | 1 |
| Surovov, IuA | 2 |
| Sedov, VP | 2 |
| Sidorenko, BA | 2 |
| Petrovitch, H | 1 |
| Vogt, TM | 1 |
| Berge, KG | 1 |
| Pugsley, MK | 1 |
| Penz, WP | 1 |
| Walker, MJ | 2 |
| Wong, TM | 1 |
| Bridges, AB | 1 |
| Kennedy, N | 1 |
| McNeill, GP | 1 |
| Cook, B | 1 |
| Pringle, TH | 1 |
| Ghio, S | 1 |
| De Servi, S | 1 |
| Angoli, L | 1 |
| Bramucci, E | 1 |
| Eleuteri, E | 1 |
| Raffaghello, S | 1 |
| Specchia, G | 1 |
| Grant, S | 1 |
| McLenachan, J | 1 |
| Wadworth, AN | 1 |
| Murdoch, D | 1 |
| Brogden, RN | 1 |
| McAinsh, J | 1 |
| Cohn, PF | 1 |
| Deedwania, PC | 2 |
| Gibson, RS | 1 |
| Gottlieb, SO | 1 |
| Handberg, E | 1 |
| Hill, JA | 2 |
| Talseth, T | 2 |
| Daae, L | 2 |
| Tanaka, H | 1 |
| Obata, H | 1 |
| Haneda, T | 1 |
| Khan, RM | 1 |
| Khan, TZ | 1 |
| Sud, P | 1 |
| Haq, G | 1 |
| Zafaruddin, M | 1 |
| Srivastava, SC | 1 |
| Katyal, VK | 1 |
| Gupta, S | 1 |
| Mohan, R | 1 |
| Gilligan, DM | 1 |
| Chan, WL | 1 |
| Stewart, R | 1 |
| Oakley, CM | 1 |
| Lindner, UK | 1 |
| Guth, BD | 4 |
| Indolfi, C | 1 |
| Heusch, G | 3 |
| Seitelberger, R | 4 |
| Eichwede, F | 1 |
| Komar, K | 1 |
| Müller, R | 1 |
| Grote, B | 1 |
| Tarnow, J | 1 |
| Lu, HR | 1 |
| Vandeplassche, G | 1 |
| Wouters, L | 1 |
| Flameng, W | 1 |
| Borgers, M | 1 |
| Carbajal, EV | 1 |
| Nelson, JR | 1 |
| Hait, H | 1 |
| Gonzalez, JI | 1 |
| Kolb, R | 1 |
| Ul'ianova, KN | 1 |
| Crake, T | 1 |
| Crean, P | 2 |
| Keegan, J | 2 |
| Wright, C | 2 |
| Rouffy, J | 1 |
| Silke, B | 4 |
| Verma, SP | 4 |
| Taylor, SH | 4 |
| Crea, F | 1 |
| Pupita, G | 1 |
| Galassi, AR | 1 |
| Kaski, JC | 1 |
| Maseri, A | 1 |
| Kirchengast, M | 1 |
| Rapola, JM | 1 |
| Pellinen, TJ | 1 |
| Toivonen, L | 1 |
| Nieminen, MS | 1 |
| Abe, Y | 1 |
| Narimatsu, A | 1 |
| Tobe, A | 1 |
| Frais, MA | 2 |
| Reynolds, G | 2 |
| Sharma, SK | 1 |
| Ablad, B | 1 |
| Abrahamsson, T | 1 |
| Adler, G | 1 |
| Björkman, JA | 1 |
| Bjurö, T | 1 |
| Ek, L | 1 |
| Ervik, M | 1 |
| Sjöquist, PO | 1 |
| Sutherland, I | 1 |
| Svensson, L | 1 |
| Westby, J | 1 |
| Kvitting, P | 1 |
| Birkeland, S | 1 |
| Grong, K | 1 |
| Lekven, J | 1 |
| Haufe, MC | 1 |
| Weil, J | 1 |
| Heim, JM | 1 |
| Ernst, JE | 1 |
| Gerzer, R | 1 |
| Theisen, K | 1 |
| Morton, AR | 1 |
| Stanforth, PR | 1 |
| Freund, BJ | 1 |
| Joyner, MJ | 1 |
| Jilka, SM | 1 |
| Hartzell, AA | 1 |
| Ewy, GA | 1 |
| Wilmore, JH | 1 |
| Paletta, MJ | 1 |
| Abraham, S | 1 |
| Beatch, GN | 1 |
| Zadionchenko, VS | 1 |
| Kamenker, ES | 1 |
| Chikvashvili, IA | 1 |
| Noguchi, K | 1 |
| Ojiri, Y | 1 |
| Nagamine, F | 1 |
| Matsuzaki, T | 1 |
| Sakanashi, M | 1 |
| Rafflenbeul, W | 1 |
| Jost, S | 1 |
| Berger, C | 1 |
| Piovaccari, G | 1 |
| Melandri, G | 1 |
| Marzocchi, A | 1 |
| Scarfoglio, D | 1 |
| Sanguinetti, M | 1 |
| Magnani, B | 1 |
| Zezulka, AV | 1 |
| Sakai, K | 1 |
| Abiko, Y | 1 |
| Svendsen, TL | 3 |
| Trap-Jensen, J | 2 |
| Carlsen, JE | 1 |
| McNair, A | 1 |
| Lee, JD | 2 |
| Sakamoto, S | 1 |
| Yokoyama, M | 1 |
| Fukuzaki, H | 1 |
| Thorp, JM | 1 |
| Zacharias, FJ | 1 |
| Harvengt, C | 1 |
| Desager, JP | 1 |
| Heller, F | 1 |
| Hulhoven, R | 1 |
| Stone, JG | 2 |
| Foëx, P | 2 |
| Sear, JW | 2 |
| Johnson, LL | 2 |
| Khambatta, HJ | 2 |
| Triner, L | 2 |
| Cunningham, D | 1 |
| Quyyumi, A | 1 |
| Park, A | 1 |
| Fox, K | 1 |
| Vatle, S | 1 |
| Mazzola, C | 1 |
| Guerrasio, E | 1 |
| Kaplan, NM | 1 |
| Myreng, Y | 1 |
| Ihlen, H | 1 |
| Nitter-Hauge, S | 1 |
| Lavanchy, N | 1 |
| Martin, J | 1 |
| Rossi, A | 1 |
| Mohri, M | 1 |
| Tomoike, H | 1 |
| Inoue, T | 1 |
| Nakamura, M | 1 |
| Grover-McKay, M | 1 |
| Keller, N | 1 |
| Sykulski, R | 1 |
| Thamsborg, G | 1 |
| Storm, T | 1 |
| Larsen, J | 1 |
| Custro, N | 1 |
| Scafidi, V | 1 |
| Way, BP | 1 |
| Forfar, JC | 1 |
| Cobbe, SM | 1 |
| Lai, C | 1 |
| Onnis, E | 1 |
| Pirisi, R | 1 |
| Orani, E | 1 |
| Delogu, G | 1 |
| Cherchi, A | 1 |
| Ibel, H | 1 |
| Zimmer, HG | 1 |
| Di Maro, T | 1 |
| Carella, G | 1 |
| Cotecchia, MR | 1 |
| Caiazzo, MR | 1 |
| de Arcangelis, E | 1 |
| Condorelli, M | 1 |
| Kinoshita, K | 1 |
| Hearse, DJ | 1 |
| Braimbridge, MV | 1 |
| Manning, AS | 1 |
| Lamb, RK | 1 |
| Prabhakar, G | 1 |
| Thorpe, JA | 1 |
| Smith, S | 1 |
| Norton, R | 1 |
| Dyde, JA | 1 |
| Niada, R | 2 |
| Porta, R | 2 |
| Pescador, R | 2 |
| Mantovani, M | 2 |
| Prino, G | 2 |
| Berti, F | 1 |
| Bonde, J | 2 |
| Pedersen, LE | 1 |
| Angelo, HR | 2 |
| Kampmann, JP | 2 |
| Gallagher, KP | 1 |
| Matzusaki, M | 1 |
| Guth, B | 2 |
| Goldfarb, R | 1 |
| Berthout, P | 1 |
| Bassand, J | 1 |
| Schipman, C | 1 |
| Faivre, R | 1 |
| Mercier, M | 1 |
| Cardot, JC | 1 |
| Maurat, JP | 1 |
| Blasini, R | 1 |
| Brügmann, U | 1 |
| Reiniger, G | 1 |
| Rudolph, W | 1 |
| Ashford, A | 1 |
| Bødtker, S | 1 |
| de Buitleir, M | 1 |
| Rowland, E | 1 |
| Krikler, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| [NCT00000478] | Phase 3 | 0 participants | Interventional | 1990-11-30 | Completed | ||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for atenolol and Coronary Disease
| Article | Year |
|---|---|
Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis.
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Atenolol; Coronary Disease; Human | 2017 |
Beta-blockers for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2017 |
Beta-blockers for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2012 |
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
Beta blocking agents: current status in the prevention of sudden coronary death.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alprenolol; Atenolol; Clinical Trials as Topic; Coronary D | 1982 |
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
Type A behaviour: recent developments.
Topics: Amiloride; Atenolol; Behavior Therapy; Benzothiadiazines; Cognition; Coronary Disease; Diuretics; Dr | 1984 |
Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists.
Topics: Arrhythmias, Cardiac; Atenolol; Coronary Disease; Humans; Hypertension; Kinetics; Propanolamines; Ti | 1982 |
Refractory anaphylactoid shock potentiated by beta-blockers.
Topics: Adrenergic beta-Antagonists; Anaphylaxis; Angina Pectoris; Atenolol; Cardiac Catheterization; Combin | 1996 |
[Atenolol in treatment of patients with airway obstruction].
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Atenolol; Cardiovascular Diseases; Coronary Disease | 1996 |
[Treatment with beta-blockers in patients with acute coronary syndrome].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Atenolol; Clinical Trials as Topic; Co | 1998 |
[Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atenolol; Como | 2000 |
Circadian variation of the total ischemic burden and influence by beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Circadian Rhythm; Coronary Disease; Humans; Monitori | 1990 |
Beta-blocking agents in heart failure: modern concepts and overview.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Disease; Heart Failure; Hemodynamics; Human | 1990 |
[Cardiac function in hypertension].
Topics: Atenolol; Cardiomegaly; Coronary Disease; Digitalis Glycosides; Heart Function Tests; Heart Valve Di | 1978 |
[Cooperative study of systolic arterial hypertension in the elderly patient (SHEP). Comments].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Dis | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Topics: Arrhythmias, Cardiac; Atenolol; Coronary Disease; Drug Evaluation; Humans; Hypertension | 1991 |
Atenolol and ischaemic heart disease: an overview.
Topics: Atenolol; Cause of Death; Circadian Rhythm; Clinical Trials as Topic; Coronary Disease; Humans; Myoc | 1991 |
Smoking, catecholamines, and the ischemic myocardium.
Topics: Angina Pectoris; Atenolol; Catecholamines; Coronary Disease; Female; Heart; Humans; Male; Nifedipine | 1988 |
83 trials available for atenolol and Coronary Disease
| Article | Year |
|---|---|
[Comparative evaluation of the impact of four-week therapy with amlodipine and atenolol on quality of life and blood lipid composition in patients with coronary heart disease associated with metabolic syndrome].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angina, Stable; Atenolol; Calcium Channel | 2013 |
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Confidence Intervals; Coronary Disease; Dose-Response R | 2008 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressur | 2009 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Europe; | 2009 |
Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study.
Topics: Adenosine; Adrenergic beta-Antagonists; Aged; Atenolol; Blood Pressure; Coronary Angiography; Corona | 2010 |
Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Calcium Channel B | 2002 |
Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; C | 2004 |
Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Blood Pressure | 2007 |
[Coraxan and atenolol: similarities and differences in correction of clinical and functional indices in therapy of patients with coronary heart disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Coronary Disease; Female; Humans; Male; Midd | 2008 |
Duration of action of beta blockers.
Topics: Adrenergic beta-Antagonists; Adult; Alprenolol; Atenolol; Blood Pressure; Coronary Disease; Heart Ra | 1980 |
Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome.
Topics: Atenolol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Drug Therapy, Combination | 1981 |
Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Coronary Disease; Double-Blind Method; Female | 1982 |
Beta blocking agents: current status in the prevention of sudden coronary death.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alprenolol; Atenolol; Clinical Trials as Topic; Coronary D | 1982 |
[Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiac Complexes, Premature; Coronary Disease; Double-Blind | 1981 |
[Effect of atenolol and nitroglycerin ointment on exertion tolerance in coronary disease].
Topics: Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Ele | 1983 |
The influence of beta blockers on cardiovascular reactivity and Type A behavior pattern in hypertensives.
Topics: Amiloride; Atenolol; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Heart Rate; Humans | 1983 |
[Polycardiographic and ergometric studies after administration of atenolol and propranolol].
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Heart Fu | 1982 |
Pharmacological effects on coronary haemodynamics. A comparative study between atenolol, verapamil, nifedipine and carbocromen.
Topics: Atenolol; Chromonar; Coronary Circulation; Coronary Disease; Coumarins; Hemodynamics; Humans; Nifedi | 1981 |
Effects of beta-blockers on type-A coronary-prone behaviour.
Topics: Amiloride; Atenolol; Blood Pressure; Coronary Disease; Humans; Hydrochlorothiazide; Hypertension; Ma | 1982 |
Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial.
Topics: Adult; Aged; Atenolol; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; D | 1995 |
Effect of beta-blockade on baroreflex sensitivity and cardiovascular autonomic function tests in patients with coronary artery disease.
Topics: Adult; Aged; Atenolol; Autonomic Nervous System; Baroreflex; Blood Pressure; Coronary Disease; Cross | 1994 |
Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy.
Topics: Adult; Aged; Amlodipine; Atenolol; Coronary Disease; Diltiazem; Drug Therapy, Combination; Electroph | 1994 |
Determination of the anti-ischemic activity of nebivolol in comparison with atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Benzopyrans; Blood Pressure; Co | 1994 |
Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study.
Topics: Aged; Atenolol; Coronary Disease; Diltiazem; Drug Therapy, Combination; Female; Humans; Isosorbide D | 1994 |
Effect of beta-blockade on heart rate variability in patients with coronary artery disease.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Atenolol; Circadian Rhythm; Coronary Disease; Double- | 1994 |
Atenolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Coronary Disease; Delayed-Action Preparation | 1993 |
A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina.
Topics: Aged; Angina Pectoris; Atenolol; Blood Pressure; Coronary Circulation; Coronary Disease; Double-Blin | 1993 |
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Doxazos | 1993 |
Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
[Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?].
Topics: Adrenergic beta-Antagonists; Aged; Arterial Occlusive Diseases; Atenolol; Blood Flow Velocity; Celip | 1996 |
Pointers from recent multicentre trials using ambulatory monitoring--placing placebo in perspective.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Coronary Disease; Drug Therapy, | 1995 |
Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Calcium Channel Blockers; Coron | 1996 |
A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood | 1998 |
Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 1998 |
Effect of atenolol or metoprolol on arbutamine stress echocardiography in patients suspected of having coronary artery disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Coronary Disease; Echocardiography; Exercise Test; Female; He | 1998 |
Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Arterial Occlusive Diseases; Atenolol; Calcium Channel Blockers; | 1999 |
Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angina Pectoris; Anti-Arrhythmia Age | 2000 |
Effect of atenolol and celiprolol on acetylcholine-induced coronary vasomotion in coronary artery disease.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Atenolol; Celiprolol; Coronary Disease; Coronary Vessels | 2000 |
Circadian variation of the total ischemic burden and influence by beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Circadian Rhythm; Coronary Disease; Humans; Monitori | 1990 |
Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent.
Topics: Atenolol; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Electrocardi | 1978 |
Haemodynamic effects of atenolol in patients with coronary artery disease.
Topics: Adult; Angina Pectoris; Atenolol; Clinical Trials as Topic; Coronary Disease; Dose-Response Relation | 1978 |
The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Atenolol; Benzeneacetamides; Blood Pressure; Cor | 1992 |
Optimal control of myocardial ischaemia: the benefit of a fixed combination of atenolol and nifedipine in patients with chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Double-Blind Method; Drug Administration S | 1992 |
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.
Topics: Aged; Amiloride; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diu | 1992 |
The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Data Interpretation, Statistical; Double-B | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
The effect of atenolol on dipyridamole 201Tl myocardial perfusion tomography in patients with coronary artery disease.
Topics: Adult; Aged; Atenolol; Coronary Disease; Dipyridamole; Double-Blind Method; Female; Humans; Male; Mi | 1992 |
Angina, ischemia, and effort tolerance with vasodilating beta-blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Cardiac Output; Celiprolol; Coronary Disease | 1991 |
The prognostic and economic implications of a strategy to detect and treat asymptomatic ischemia: the Atenolol Silent Ischemia Trial (ASIST) protocol.
Topics: Atenolol; Clinical Protocols; Coronary Disease; Double-Blind Method; Drug Administration Schedule; E | 1991 |
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Fe | 1991 |
Clinical investigation of asymptomatic cardiac ischemia.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atenolol; Coronary Artery Bypass; Coronary Disease; | 1991 |
[Preoperative treatment with beta-receptor blockers and isoflurane anesthesia. Hemodynamic interactions in patients with coronary disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anesthesia, Inhalation; Atenolol; Bisoprolol; Coronary Dis | 1990 |
Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia.
Topics: Angina Pectoris; Atenolol; Circadian Rhythm; Coronary Disease; Double-Blind Method; Electrocardiogra | 1991 |
Effects of atenolol alone, nifedipine alone and their combination on ambulant myocardial ischemia.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Double-Blind Method; Drug Therapy, Combina | 1991 |
Therapeutic implications of dynamic coronary stenosis in patients with single vessel coronary artery disease.
Topics: Adult; Aged; Atenolol; Cardiac Catheterization; Coronary Disease; Double-Blind Method; Electrocardio | 1991 |
[Alpha-1 inhibition. Prevention of coronary risk factors].
Topics: Atenolol; Coronary Disease; Delayed-Action Preparations; Female; Humans; Hypertension; Lipids; Male; | 1990 |
Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device.
Topics: Adult; Aged; Atenolol; Blood Pressure; Cardiac Output; Coronary Angiography; Coronary Disease; Femal | 1990 |
Effects of theophylline, atenolol and their combination on myocardial ischemia in stable angina pectoris.
Topics: Aged; Angina Pectoris; Atenolol; Coronary Circulation; Coronary Disease; Drug Therapy, Combination; | 1990 |
Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study.
Topics: Atenolol; Blood Pressure; Cardiac Output; Coronary Disease; Double-Blind Method; Echocardiography; H | 1990 |
Differential actions of atenolol and celiprolol on cardiac performance in ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Coronary Disease; Exercise Test; Female; Heart; H | 1986 |
Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Coronary Disease; Dose | 1989 |
Alterations in plasma lipids consequent to endurance training and beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Coronary Disease; Humans; Lipids; Male; Physical Educa | 1989 |
[Effect of calcium antagonists and beta receptor blockers on coronary vessel diameter].
Topics: Angina Pectoris; Atenolol; Coronary Angiography; Coronary Circulation; Coronary Disease; Gallopamil; | 1989 |
Hemodynamic assessment of nicardipine alone and with atenolol in coronary artery disease using a modified echo-Doppler device.
Topics: Adult; Aged; Atenolol; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1989 |
Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anesthesia; Atenolol; Clinical Trials as To | 1988 |
Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group.
Topics: Atenolol; Clinical Trials as Topic; Coronary Disease; Heart Rupture; Humans; Ireland; Myocardial Inf | 1988 |
Circadian variation of total ischaemic burden and its alteration with anti-anginal agents.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Circadian Rhythm; Clinical Trials as Topic; Coronary Disease | 1988 |
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary D | 1988 |
Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pres | 1988 |
Critical comments on recent literature. SCRAAPHY about MAPHY from HAPPHY.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Benzothiadiazines; Clinical Protocols; Coronary Diseas | 1988 |
Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol.
Topics: Acebutolol; Aged; Atenolol; Atrial Natriuretic Factor; Clinical Trials as Topic; Coronary Disease; E | 1988 |
[Effects of chronic administration of several calcium antagonists on pituitary release of TSH].
Topics: Adult; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Humans; Hyper | 1987 |
Comparison of the effects of chronic oral therapy with atenolol and sotalol on ventricular monophasic action potential duration and effective refractory period.
Topics: Action Potentials; Administration, Oral; Aged; Atenolol; Clinical Trials as Topic; Coronary Disease; | 1988 |
Anti-ischaemic and anti-anginal activity of atenolol, nifedipine and their combination in stable, chronic effort angina.
Topics: Angina Pectoris; Atenolol; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1988 |
Atenolol and/or nifedipine in effort angina: which is the treatment of choice for exercise coronary protection?
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Double-Blind Method; Drug Therapy, Combina | 1988 |
Risk of myocardial ischaemia during anaesthesia in treated and untreated hypertensive patients.
Topics: Anesthesia; Atenolol; Coronary Disease; Diuretics; Humans; Hypertension; Intubation, Intratracheal; | 1988 |
The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery.
Topics: Angina Pectoris; Atenolol; Coronary Artery Bypass; Coronary Disease; Electrocardiography; Female; Hu | 1988 |
Smoking, catecholamines, and the ischemic myocardium.
Topics: Angina Pectoris; Atenolol; Catecholamines; Coronary Disease; Female; Heart; Humans; Male; Nifedipine | 1988 |
Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease.
Topics: Aged; Atenolol; Coronary Disease; Disopyramide; Drug Therapy, Combination; Female; Heart Rate; Hemod | 1986 |
[Comparative anti-ischemic activity of atenolol and diltiazem. Crossed single-blind randomized study using a computerized exercise test].
Topics: Aged; Atenolol; Benzazepines; Clinical Trials as Topic; Computers; Coronary Disease; Diltiazem; Exer | 1985 |
[Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine].
Topics: Angina Pectoris; Atenolol; Biotransformation; Coronary Disease; Delayed-Action Preparations; Drug Ad | 1985 |
Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function.
Topics: Administration, Oral; Adult; Angiography; Atenolol; Blood Pressure; Cardiac Catheterization; Cardiom | 1985 |
106 other studies available for atenolol and Coronary Disease
| Article | Year |
|---|---|
[Symptomatic coronary heart disease. Therapy with a beta blocker and ivabradine combination].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Coronary Disease; Drug Therapy | 2014 |
[Symptomatic coronary heart diseases. Combination therapy is successful in general practice].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Clinical Trials as Topic; Coro | 2014 |
[Resting heart rate as prognostic parameter--a slow rate indicates strength].
Topics: Adrenergic beta-Antagonists; Atenolol; Benzazepines; Coronary Disease; Cyclic Nucleotide-Gated Catio | 2008 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Dise | 2009 |
Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiopulmonary Bypass; Chromatography, High Pressure Liquid; | 2009 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2002 |
[Ischemic heart disease in patients with arteriopathies].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Antihypertensive Agents; Arterioscle | 2002 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper | 2003 |
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chi-Square Distribution; Coronary Disea | 2005 |
[Antihypertensive therapy: campaign of the giants].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; D | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Case-Control Studies; Cohort Studies; Coron | 2006 |
Time-of-day variation in cardiovascular response to maximal exercise testing in coronary heart disease patients taking a beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Cardiovascular System; Circadian | 2007 |
[Management of coronary heart disease: seasonal features].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Coronary Disease; Disease Management; Fatty Acids; Fatt | 2007 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
Protective effects of beta-adrenergic blockade in isolated ischemic hearts.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Calcium; Cats; Coronary Disease; Heart; In Vitro Tec | 1980 |
Factors relating to the beta blocker withdrawal syndrome.
Topics: Acebutolol; Adrenergic beta-Antagonists; Atenolol; Coronary Disease; Heart Rate; Humans; Hyperthyroi | 1981 |
The effect of alpha- and beta-adrenoceptor antagonist agents on reperfusion ventricular fibrillation and metabolic status in the isolated perfused rat heart.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arterial Occlusive Diseases; Ate | 1983 |
Effects of beta-blockade on regional myocardial flow and function during exercise.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Collateral Circulation; Coronary Cir | 1984 |
[Atenolol versus prajmalium bitartrate. Double-blind study on the treatment of ventricular extrasystoles in coronary heart disease].
Topics: Ajmaline; Atenolol; Cardiac Complexes, Premature; Coronary Disease; Double-Blind Method; Female; Hea | 1982 |
Left stellate stimulation: regional myocardial flows and ischemic injury in dogs.
Topics: Animals; Atenolol; Coronary Circulation; Coronary Disease; Dogs; Electric Stimulation; Electrocardio | 1980 |
Influence of propranolol isomers and atenolol on myocardial cyclic AMP, high energy phosphates and vulnerability to fibrillation after coronary artery ligation in the isolated rat heart.
Topics: Adenosine Triphosphate; Animals; Atenolol; Coronary Disease; Cyclic AMP; Heart; Male; Myocardium; Ph | 1981 |
Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiac Catheterization; Cardiac Pacing, A | 1984 |
The effects of beta blockers on exercise capacity and on training response in elderly subjects.
Topics: Aged; Atenolol; Coronary Disease; Ethanolamines; Exercise Test; Female; Humans; Hypertension; Labeta | 1984 |
[Use of atenolol in tooth extraction for hypertensive and coronary patients].
Topics: Adult; Aged; Atenolol; Blood Pressure; Coronary Disease; Electrocardiography; Female; Heart Rate; Hu | 1984 |
[Use of Falicard and Sectral in patients with COPD and ischemic heart disease].
Topics: Angina Pectoris; Atenolol; Coronary Disease; Drug Evaluation; Drug Therapy, Combination; Humans; Lun | 1983 |
[Effect of the beta-adrenoblockader atenolol on the extent of myocardial necrosis in transient and permanent coronary occlusion].
Topics: Animals; Atenolol; Coronary Disease; Injections, Intravenous; Male; Myocardium; Necrosis; Rats; Time | 1984 |
[The effects of atenolol on the exercise symptoms of coronary patients. A double blind study (author's transl)].
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Dose-Response Relationship, Drug; Double-B | 1981 |
[Efficacy of atenolol in moderate-to-mild essential hypertension and in ischemic cardiopathy. Evaluation with the bicycle ergometer].
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Drug Evaluation; Drug Tolerance; Exercise | 1983 |
Effects of right stellate ganglion stimulation on regional myocardial blood flow and ischemic injury in dogs.
Topics: Animals; Atenolol; Coronary Circulation; Coronary Disease; Dogs; Electric Stimulation; Electrocardio | 1981 |
[201-thallium stress scintigram in patients with coronary artery disease after administration of the cardioselective betablocker atenolol (author's transl)].
Topics: Adult; Angina Pectoris; Atenolol; Coronary Circulation; Coronary Disease; Humans; Male; Middle Aged; | 1981 |
Evaluation of effect of drugs on the exercise ECG.
Topics: Atenolol; Blood Pressure; Cardiovascular Agents; Coronary Disease; Electrocardiography; Exercise Tes | 1981 |
[Nifedipine and beta blockers: a potentially dangerous association?].
Topics: Aged; Atenolol; Coronary Disease; Drug Therapy, Combination; Humans; Male; Nifedipine; Propanolamine | 1980 |
Diurnal variation of ischemic response to exercise in patients receiving a once-daily dose of beta-blockers. Implications for exercise testing and prescription of exercise and training heart rates.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Atenolol; Blood Pressure; Circadian Rhy | 1996 |
[Corotenol, its effectiveness and tolerance in light of new studies].
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Disease; Humans; Hypertension | 1996 |
The QRS score: a promising new exercise score for detecting coronary artery disease based on exercise-induced changes of Q-, R- and S-waves: a relationship with myocardial ischaemia.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Coronary Disease; Electrocardiography; Exercise Test; F | 1996 |
Myocardial infarction caused by coronary artery myocardial bridge.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atenolol; Cardiac Catheterization; Coronary Angio | 1997 |
Silent myocardial ischemia: some good news.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Combined Modality Therapy; Coronary | 1997 |
Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Coronary Disease; H | 1997 |
Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Atenolol; Coronary Disease; Heart Diseases; Humans; Intraoperative Peri | 1997 |
Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Bisoprolol; C | 1998 |
Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 1999 |
Long-term preservation of left ventricular function in medically treated patients with coronary artery disease and persistent exercise-induced ischemia.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Atenolol; Cardiovascular Agents; Coronary Disease; Data In | 1999 |
Alpha-adrenoceptor blockade prevents exercise-induced vasoconstriction of stenotic coronary arteries.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cardiac Catheteriz | 1999 |
Apical hypokinesis in a patient with hypertrophic cardiomyopathy and myocardial bridging: reversal with beta-blockade--a case report.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Cardiomyopathy, Hypertrophic; Coronary Disease; Humans | 1999 |
When heart patients need non-heart operations.
Topics: Adrenergic beta-Antagonists; Atenolol; Coronary Disease; Heart Diseases; Humans; Postoperative Compl | 1999 |
Magnetic resonance contrast enhancement with gadolinium-DTPA in patients with angina and angiographically normal coronary arteries: effect of chronic beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Chronic Disease; Contrast Media; Coronary Angiog | 1999 |
Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Amb | 1999 |
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Human | 2001 |
Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Body Mass Index; C-Reactive Protein; Cholesterol, | 2002 |
Atenolol, regional myocardial blood flow and S-T segment in canine ischaemic myocardium [proceedingins].
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Circulation; Coronary Disease; Dogs; Hemody | 1976 |
[Beta-blockers: redistribution of coronary blood flow and experimental myocardial ischaemia].
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Circulation; Coronary Disease; Disease Mode | 1978 |
[Effects of beta blockaders on ventilatory function in chronic bronchitis].
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Atenolol; Bronchitis; Chronic Disease; Coronary Dise | 1979 |
The effects of the beta-blocker atenolol and nitroglycerin on left ventricular function and geometry in man.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Coronary Disease; Diastole; Heart Ventricles; Hemodyna | 1979 |
The role of beta-adrenoceptors in coronary blood flow distribution in normal and ischemic canine myocardium.
Topics: Albuterol; Animals; Atenolol; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Fem | 1979 |
[Atenolol. Successful therapy of light forms of coronary disease using a beta blockader].
Topics: Atenolol; Blood Pressure; Coronary Disease; Female; Heart Rate; Humans; Long-Term Care; Male; Middle | 1978 |
Extracellular potassium activity changes in the canine myocardium after acute coronary occlusion and the influence of beta-blockade.
Topics: Animals; Atenolol; Coronary Disease; Dogs; Extracellular Space; Female; Heart; Male; Myocardium; Pot | 1979 |
[Long term effects of the beta-adrenergic blocking agent atenolol (Tenormin) on coronary heart disease: a study of 125 patients (author's transl)].
Topics: Adult; Aged; Atenolol; Blood Pressure; Coronary Disease; Drug Evaluation; Exercise Test; Female; Hea | 1978 |
Effects of selective and non-selective beta-adrenergic blockade on coronary dynamics in man assessed by rapid atrial pacing.
Topics: Adult; Atenolol; Cardiac Pacing, Artificial; Coronary Disease; Female; Heart; Heart Rate; Humans; Ma | 1978 |
[Effects of the beta-blocking agent atenolol on arrhythmias especially ventricular fibrillation and fibrillation threshold after acute experimental coronary artery occlusion (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Carotid Arteries; Coronary Disease; Coronary Vessels; Dogs; | 1977 |
Left ventricular function and regional myocardial blood flow after atenolol in normals and patients with coronary artery disease.
Topics: Atenolol; Coronary Disease; Coronary Vessels; Heart Ventricles; Hemodynamics; Humans; Propanolamines | 1977 |
Will bedtime dose of atenolol be more effective in secondary prevention of coronary artery disease?
Topics: Atenolol; Circadian Rhythm; Coronary Disease; Humans; Time Factors | 1992 |
Stereoselective release of (S)-atenolol from adrenergic nerve endings at exercise.
Topics: Adrenergic Fibers; Atenolol; Chromatography, High Pressure Liquid; Coronary Disease; Exercise Test; | 1992 |
Influence of atenolol on the relationship between heart rate and QT interval in patients with exercise-induced myocardial ischemia.
Topics: Administration, Oral; Angina Pectoris; Atenolol; Coronary Disease; Electrocardiography; Exercise Tes | 1992 |
[Significance of complex hemodynamic studies for the choice of therapy with the beta-adrenergic blocker, atenolol, and the calcium antagonist, procorum, in patients with ischemic heart disease].
Topics: Aged; Aged, 80 and over; Atenolol; Coronary Disease; Gallopamil; Hemodynamics; Humans; Middle Aged | 1992 |
Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 1992 |
Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Atenolol; Coronary Disease; Electrocardiograph | 1992 |
Effects of regression of left ventricular hypertrophy following atenolol or bunazosin therapy on ischemic cardiac function and myocardial metabolism in spontaneously hypertensive rats.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Atenolol; Blood Pre | 1991 |
Intraoperative myocardial ischaemia in surgical patients with treated ischaemic heart disease.
Topics: Atenolol; Blood Pressure; Coronary Disease; Electrocardiography; Female; Humans; Intraoperative Comp | 1991 |
Interpretation of treadmill stress test in patients with coronary artery disease receiving beta blocker therapy.
Topics: Adult; Aged; Atenolol; Coronary Disease; Electrocardiography; Exercise Test; Humans; Male; Middle Ag | 1991 |
Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Cardiomyopathy, Hypertrophic; Coronary Disease; Drug Hyperse | 1991 |
[Therapy of hypertensive coronary patients. Open long-term study with a combination of atenolol and nifedipine].
Topics: Aged; Atenolol; Coronary Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hyperten | 1991 |
Mechanisms of benefit in the ischemic myocardium due to heart rate reduction.
Topics: Animals; Atenolol; Coronary Circulation; Coronary Disease; Dogs; Heart Rate; Myocardial Contraction; | 1990 |
Effects of beta-adrenoceptor antagonists on cardiac function in ischemic-reperfused myocardium of the isolated working rabbit heart.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Benzopyrans; Coronary Circulation; Coronary Disease; | 1990 |
[Changes in diastolic filling of the heart during isometric exercise test in patients with ischemic heart disease treated with atenolol].
Topics: Aged; Atenolol; Coronary Disease; Echocardiography; Exercise Test; Female; Heart; Humans; Male; Midd | 1991 |
Differences in ischaemic myocardial potassium leakage after treatment with the calcium antagonist anipamil or the beta-blocker atenolol.
Topics: Animals; Atenolol; Calcium Channel Blockers; Coronary Disease; Extracellular Space; Heart; Hemodynam | 1990 |
Betaxolol, a cardioselective beta-adrenoceptor antagonist, attenuates ischemic myocardial acidosis in dogs.
Topics: Acidosis; Animals; Atenolol; Betaxolol; Blood Pressure; Coronary Circulation; Coronary Disease; Dogs | 1990 |
Cardiac anti-ischemic effect of metoprolol: role of beta-blockade within the ischemic region.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cardiac Output; Cats; Coronary Disea | 1987 |
Does alpha 1-adrenergic blockade influence regional blood flow regulation in hearts with coronary artery occlusion?
Topics: Animals; Atenolol; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Female; Male; Prazosin; | 1989 |
[Hemodynamic and medicamentous modification of stimulated atrial natriuretic factor secretion].
Topics: Adult; Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Cardiac Catheterization; Cardiac P | 1989 |
Mechanisms underlying the antiarrhythmic properties of beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats.
Topics: Adrenergic beta-Antagonists; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aten | 1989 |
[Changes in the platelet-vascular system of hemostasis in patients with ischemic heart disease and hypertension after the treatment].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Coagulation; Calcium Channel Blockers; Cor | 1989 |
Alleviation of myocardial dysfunction and abnormal lactate metabolism during coronary stenosis in dogs by ICI 118,551.
Topics: Angina Pectoris; Animals; Atenolol; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Disea | 1989 |
[Multiple coronary fistulas to the left ventricle. An unusual cause of myocardial ischemia].
Topics: Angina Pectoris; Angiography; Atenolol; Coronary Angiography; Coronary Disease; Coronary Vessels; Fi | 1989 |
Attenuation by atenolol of myocardial acidosis during ischemia in dogs: contribution of beta-1 adrenoceptors to myocardial acidosis.
Topics: Acidosis; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cardiomyopathies; Coronary | 1985 |
Immediate central hemodynamic effects of five different beta-adrenoceptor-blocking agents, acebutolol, atenolol, pindolol, practolol, and propranolol, in patients with ischemic heart disease.
Topics: Acebutolol; Adrenergic beta-Antagonists; Aged; Atenolol; Cardiac Output; Coronary Disease; Heart Rat | 1985 |
Experimental exercise-induced ischemia: drug therapy can eliminate regional dysfunction and oxygen supply-demand imbalance.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Benzazepines; Calcium Channel Blockers; Coronary Cir | 1986 |
Regulation of coronary blood flow by counteraction of coronary vascular alpha and beta adrenergic activation during experimental pliable coronary stenosis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Circulation; | 1986 |
Benefits and potential harm of lowering high blood pressure.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1987 |
Beta-blocking agents and plasma lipids: an update.
Topics: 1-Propanol; Adrenergic beta-Antagonists; Atenolol; Cholesterol, LDL; Coronary Disease; Humans; Hyper | 1987 |
Effects of beta-adrenergic blockade on left ventricular relaxation and filling dynamics in coronary artery disease: a pulsed Doppler echocardiographic study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Coronary Disease; Diastole; Echo | 1988 |
Comparative study of the effects of acebutolol, atenolol, d-propranolol and dl,-propranolol on the alterations in energy metabolism caused by ischemia and reperfusion: a 31P NMR study on the isolated rat heart.
Topics: Acebutolol; Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Disease; Energy Metabolism; In | 1988 |
Amelioration by beta-adrenergic blockade of regional myocardial dysfunction induced by coronary artery occlusion after, but not before collateral development in conscious dogs.
Topics: Animals; Atenolol; Collateral Circulation; Coronary Disease; Dogs; Hemodynamics; Myocardial Contract | 1989 |
Dissociation between regional myocardial dysfunction and subendocardial ST segment elevation during and after exercise-induced ischemia in dogs.
Topics: Animals; Atenolol; Blood Pressure; Cardiomegaly; Coronary Circulation; Coronary Disease; Dogs; Elect | 1987 |
Metabolic recovery following temporary regional myocardial ischemia in the rat.
Topics: Acute Disease; Adenine Nucleotides; Adenosine Triphosphate; Animals; Atenolol; Coronary Disease; Fem | 1986 |
Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Coronary Disease; Heart Rate; Male; Myocard | 1988 |
Fixed combination of atenolol and nifedipine in cardiovascular medicine. Partial proceedings of a workshop. London, 21 January, 1987.
Topics: Atenolol; Coronary Disease; Drug Therapy, Combination; Humans; Hypertension; Nifedipine | 1988 |
Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Benzazepines; Coronary Circulation; Coronary Disease; Dog | 1987 |
Cardioprotective effects of defibrotide in acute lethal and nonlethal myocardial ischemia in the cat.
Topics: Adenosine Triphosphate; Animals; Atenolol; Cats; Coronary Disease; Creatine Kinase; Epoprostenol; Fi | 1986 |
Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs.
Topics: Animals; Atenolol; Coronary Circulation; Coronary Disease; Dogs; Heart; Heart Rate; Myocardial Contr | 1987 |
Regional myocardial blood flow and function in experimental myocardial ischemia.
Topics: Animals; Atenolol; Constriction, Pathologic; Coronary Circulation; Coronary Disease; Coronary Vessel | 1986 |
Cardioprotective effects of defibrotide in acute myocardial ischemia in the cat.
Topics: Acute Disease; Adenosine Triphosphate; Animals; Atenolol; Cats; Coronary Disease; Creatine Kinase; E | 1985 |
Abrupt withdrawal of atenolol in patients with severe angina: comparison with the effects of treatment.
Topics: Angina Pectoris; Atenolol; Coronary Disease; Humans; Substance Withdrawal Syndrome | 1986 |
Atenolol inhibits the elimination of disopyramide.
Topics: Adult; Aged; Atenolol; Coronary Disease; Dealkylation; Disopyramide; Female; Half-Life; Humans; Kine | 1985 |
Effect of the combination of diltiazem and atenolol on exercise-induced regional myocardial ischemia in conscious dogs.
Topics: Animals; Atenolol; Benzazepines; Coronary Circulation; Coronary Disease; Diltiazem; Dogs; Drug Thera | 1985 |